反流性食管炎治疗效果与食管下段菌群构成变化的关系研究

doi:10.3969/j.issn.1006-7795.2020.02.016

首都医科大学学报 ›› 2020, Vol. 41 ›› Issue (2): 243-248.doi: 10.3969/j.issn.1006-7795.2020.02.016

反流性食管炎治疗效果与食管下段菌群构成变化的关系研究

余英, 高峰, 张杰

首都医科大学附属北京安贞医院消化内科, 北京 100029

收稿日期:2019-10-12 出版日期:2020-04-21 发布日期:2020-04-16
通讯作者: 张杰 E-mail:zhangjie4155@sina.com
基金资助:
首都卫生发展科研专项项目（2018-2-1053）。

Study on the relationship between the changes of microbiota and therapeutic effect in patients with reflux esophagitis

Yu Ying, Gao Feng, Zhang Jie

Department of Gastroenterology, Beijing Anzhen Hospital, Capital Medical University, Beijing, China

Received:2019-10-12 Online:2020-04-21 Published:2020-04-16
Supported by:
This study was supported by Capitals Funds for Health Improvement and Research （2018-2-1053）.

摘要/Abstract

摘要： 目的研究食管下段菌群变化与反流性食管炎患者治疗效果的关系。方法对反流性食管炎患者给予质子泵抑制剂规范治疗，在治疗前、后分别采集食管下段黏膜样本，根据治疗效果分为愈合组和愈合不良组，采用宏基因组学高通量DNA测序和生物信息学分析技术，比较治疗前、后食管下段黏膜菌群构成变化。结果对愈合组患者治疗前与治疗后食管下段黏膜菌群丰度进行比较发现：乳杆菌科、乳杆菌属、双歧杆菌属、螺杆菌属丰度差异有统计学意义[2.7%（1.5%~3.2%）vs 4.8%（3.0%~10.7%）、2.7%（1.5%~（P=0.001、P=0.001、P=0.042、P=0.049）。同时对愈合组和愈合不良组治疗后食管下段黏膜菌群丰度进行比较发现：双歧杆菌属、螺杆菌属丰度差异有统计学意义[1.4%（1.0%~2.2%）vs 0.7%（0.4%~1.1%）、0.12%（0.08%~0.21%）vs 0.07%（0.03%~0.09%）]（P=0.003、P=0.014）。结论质子泵抑制剂治疗反流性食管炎的治疗效果与食管下段黏膜菌群构成变化相关，愈合组有益菌丰度明显增高。

关键词: 反流性食管炎, 高通量DNA测序技术, 菌群构成, 治疗效果

Abstract: Objective To study the relationship between the changes of lower esophageal mucosal microbiota and the therapeutic effect in the patients with reflux esophagitis. Methods The patients with reflux esophagitis were recruited and undertook standard proton pump inhibitor (PPI) therapy for 8 weeks. They were divided into mucosal healing group and poor healing group. The high-throughput nucleotide sequencing and bioinformatics analysis techniques were used to analyze the composition of the distal esophageal mucosal microbiota in the reflux esophagitis before and after PPI therapy. Results In the healing group, there were significant differences on the abundances of the lower esophageal mucosa between before and after PPI therapy at the level of genus:Lactobacillaceae, Lactobacillus, Bifidobacterium and Helicobacter [2.7%(1.5%-3.2%) vs 4.8%(3.0%-10.7%), 2.7%(1.5%-3.2%) vs 4.8%(3.0%-10.7%), 0.7%(0.6%-10.7%) vs 1.4%(1.0%-2.2%), 0.08%(0.04%-0.13%) vs 0.12%(0.08%-0.21%)](P=0.001, P=0.001, P=0.042, P=0.049, respectively). The abundances of Bifidobacterium and Helicobacter at the level of genus in the healing group after the PPI therapy were significant increasing than those in the poor healing group[1.4%(1.0%-2.2%) vs 0.7%(0.4%-1.1%), 0.12%(0.08%-0.21%) vs 0.07%(0.03%-0.09%)] (P=0.003, P=0.014). Conclusion The changes in the lower esophageal mucosal microbiota after PPI therapy in patients with reflux esophagitis are related to the therapeutic effect. And in the healing group, the proportion of beneficial bacteria significantly increased.

Key words: reflux esophagitis, high-throughput DNA sequencing, microbiota, therapeutic effect

中图分类号:

余英, 高峰, 张杰. 反流性食管炎治疗效果与食管下段菌群构成变化的关系研究[J]. 首都医科大学学报, 2020, 41(2): 243-248.

Yu Ying, Gao Feng, Zhang Jie. Study on the relationship between the changes of microbiota and therapeutic effect in patients with reflux esophagitis[J]. Journal of Capital Medical University, 2020, 41(2): 243-248.

参考文献

[1] Ley R E, Peterson D A, Gordon J I. Ecological and evolutionary forces shaping microbial diversity in the human intestine[J]. Cell, 2006, 124(4):837-848.
[2] DiBaise J K, Zhang H, Crowell M D, et al. Gut microbiota and its possible relationship with obesity[J].Mayo Clin Proc, 2008, 83(4):460-469.
[3] Di Pilato V, Freschi G, Ringressi M N, et al. The esophageal microbiota in health and disease[J]. Ann NY Acad Sci, 2016, 1381(1):21-33.
[4] Blackett K L, Siddhi S S, Cleary S, et al. Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, Barrett's and oesophageal carcinoma:association or causality?[J]. Aliment Pharmacol Ther, 2013, 37(11):1084-1092.
[5] Wang Z K, Yang Y S. Upper gastrointestinal microbiota and digestive diseases[J]. World J Gastroenterol, 2013, 19(10):1541-1550.
[6] Hunt R H, Yaghoobi M. The esophageal and gastric microbiome in health and disease[J]. Gastroenterol Clin North Am, 2017, 46(1):121-141.
[7] Corning B, Copland A P, Frye J W. The esophageal microbiome in health and disease[J]. Curr Gastroenterol Rep, 2018, 20(8):39.
[8] May M, Abrams J A. Emerging insights into the esophageal microbiome[J]. Curr Treat Options Gastroenterol, 2018, 16(1):72-85.
[9] Lundell L R, Dent J, Bennett J R, et al. Endoscopic assessment of esophagitis:clinical and functional correlates and further validation of the Los Angeles classification[J].Gut, 1999, 45(2):172-180.
[10] Yang L, Lu X, Nossa C W, et al. Inflammation and intestinal metaplasia of the distal esophagus are associated with alterations in the microbiome[J].Gastroenterology, 2009, 137(2):588-597.
[11] Schiavi E, Gleinser M, Molloy E, et al. The surface-associated exopolysaccharide of Bifidobacterium longum 35624 plays an essential role in dampening host proinflammatory responses and repressing local TH17 responses[J].Appl Environ Microbiol, 2016, 82(24):7185-7196.
[12] MacSharry J, O'Mahony C, Shalaby K H, et al. Immunomodulatory effects of feeding with Bifidobacterium longum on allergen-induced lung inflammation in the mouse[J]. Pulmonary Pharmaco Therapeut, 2012, 25(4):325-334.
[13] Capurso L. Thirty years of lactobacillus rhamnosus GG:a review[J].J Clin Gastroenterol, 2019, 53(Suppl 1):S1-S41.
[14] Mogna L, Deidda F, Nicola S, et al. In vitro inhibition of Klebsiela pneumoniae by Lactobacilus delbruecki Subsp. delbruecki LDD01(DSM 22106):An Innovative Strategy to Possibly Counteract Such infections in humans?[J]. J Clin Gastroenterol, 2016, 50(Suppl 2):S136-S139.
[15] Ho K Y, Chan Y H, Kang J Y. Increasing trend of reflux esophagitis and decreasing trend of Helicobacter pylori infection in patients from a multiethnic Asian country[J].Am J Gastroenterol, 2005, 100:1923-1928.
[16] Zou D, He J, Ma X, et al. Epidemiology of symptom-defined gastroesophageal reflux disease and reflux esophagitis:the systematic investigation of gastrointestinal diseases in China (SILC)[J].Scand J Gastroenterol, 2011, 46(2):133-141.
[17] Ashktorab H, Entezari O, Nouraie M, et al. Helicobacter pylori protection against reflux esophagitis[J].Dig Dis Sci, 2012, 57(11):2924-2928.

反流性食管炎治疗效果与食管下段菌群构成变化的关系研究

Study on the relationship between the changes of microbiota and therapeutic effect in patients with reflux esophagitis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	任艳萍, 张俊岩, 吴涵, 罗炯, 杨春林, 马辛, 姜玮. 磁惊厥治疗与无抽搐电痉挛治疗抑郁发作的早期疗效及对认知功能的影响[J]. 首都医科大学学报, 2022, 43(2): 239-243.
[2]	王荣欣, 王晶, 胡水清. 伴有食管外症状的反流性食管炎患者的危险因素分析[J]. 首都医科大学学报, 2022, 43(1): 132-137.
[3]	王希思, 杨维, 黄程, 赵文, 赵倩, 段超, 苏雁, 金眉, 张大伟, 秦红, 王焕民, 马晓莉. 儿童肝母细胞瘤的临床特征和治疗效果评价[J]. 首都医科大学学报, 2019, 40(2): 169-173.